In the phase III TROPiCS-02 trial, patients with heavily pretreated (median of three prior systemic therapies) ER+/HER2-breast cancer and who received prior CDK4/6 inhibitors were randomized to sacituzumab govitecan or physician’s choice chemotherapy. The gene discussed is ESR1; the disease is breast carcinoma.